NCT06212076View on ClinicalTrials.gov

Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

July 9, 2027

Study Completion Date

July 9, 2027

Conditions
Solid Tumor
Interventions
DRUG

IPG1094

IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg

Trial Locations (2)

200080

RECRUITING

Shanghai General Hospital, Shanghai

Unknown

RECRUITING

Shanghai GoBroad Cancer Hospital China Pharmaceutical University, Shanghai

All Listed Sponsors
lead

Nanjing Immunophage Biotech Co., Ltd

INDUSTRY